Citation Impact
Citing Papers
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
2012 Standout
Intracellular Nucleic Acid Sensors and Autoimmunity
2011 StandoutNobel
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study
2021 Standout
Synovitis in osteoarthritis: current understanding with therapeutic implications
2017 Standout
Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles
2011 Standout
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease
2007
An extensive phenotypic characterization of the hTNFα transgenic mice
2007 StandoutNobel
Treml4, an Ig Superfamily Member, Mediates Presentation of Several Antigens to T Cells In Vivo, Including Protective Immunity to HER2 Protein
2011 StandoutNobel
B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis
2016
Engineering precision nanoparticles for drug delivery
2020 Standout
Osteoclasts: more than ‘bone eaters’
2014
Shared and distinct mechanisms of fibrosis
2019
N-glycans as functional effectors of genetic and epigenetic disease risk
2020
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study
2015
The TNF-? transgenic mouse model of inflammatory arthritis
2003
Idiopathic pulmonary fibrosis
2017 Standout
Rheumatoid arthritis
2018 Standout
Osteoprotegerin protects against generalized bone loss in tumor necrosis factor–transgenic mice
2003
Rheumatoid arthritis
2016 Standout
From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation
2014 Standout
Prevalence of movement disorders in men and women aged 50–89 years (Bruneck Study cohort): a population-based study
2005
SKG arthritis as a model for evaluating therapies in rheumatoid arthritis with special focus on bone changes
2012 StandoutNobel
Abatacept (CTLA‐4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis
2012
Single and combined inhibition of tumor necrosis factor, interleukin‐1, and RANKL pathways in tumor necrosis factor–induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction
2004
Mechanotransduction and extracellular matrix homeostasis
2014 Standout
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
2009
Thymoquinone and its therapeutic potentials
2015 Standout
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
2012
Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases
2012
Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation
2011 StandoutNobel
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
2013
How antirheumatic drugs protect joints from damage in rheumatoid arthritis
2008
Skeletal infections: microbial pathogenesis, immunity and clinical management
2022 Standout
Autoantibodies in rheumatoid arthritis and their clinical significance.
2002
Evolving concepts of rheumatoid arthritis
2003 StandoutNature
Chronic Implant-Related Bone Infections—Can Immune Modulation be a Therapeutic Strategy?
2019
IL-6 in Inflammation, Immunity, and Disease
2014 Standout
How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor
2010 Standout
Autoimmunity and chronic inflammation — Two clearance-related steps in the etiopathogenesis of SLE
2010
Osteoporosis in inflammatory joint diseases
2010
Idiopathic pulmonary fibrosis
2017 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo
2004 Standout
Rheumatoid arthritis
2010 Standout
Molecular mechanisms of necroptosis: an ordered cellular explosion
2010 Standout
The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
2012
EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT
2011
CTLA‐4: a key regulatory point in the control of autoimmune disease
2008
Therapeutic strategies for rheumatoid arthritis
2003
TREG-cell therapies for autoimmune rheumatic diseases
2014 StandoutNobel
Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?
2015
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
2014
Cytokines in the pathogenesis of rheumatoid arthritis
2007 Standout
Molecular mechanisms of late apoptotic/necrotic cell clearance
2009
Lessons from animal models of arthritis
2002
Integrins and cadherins as therapeutic targets in fibrosis
2014
Verbascoside — A review of its occurrence, (bio)synthesis and pharmacological significance
2014 Standout
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Osteoclasts are essential for TNF-α–mediated joint destruction
2002
Glycoproteomics
2022 StandoutNobel
Osteoclasts in the Inflammatory Arthritis: Implications for Pathologic Osteolysis
2019
IL-1 mediates TNF-induced osteoclastogenesis
2005 Standout
Anakinra for the treatment of adult-onset Still’s disease
2018
Osteoclasts are essential for TNF-α–mediated joint destruction
2002
Apoptosis in the pathogenesis of systemic lupus erythematosus
2008
Works of G. Schett being referenced
Clinical, Radiographic, and Immunogenic Effects After 1 Year of Tocilizumab-Based Treatment Strategy with and without Methotrexate in Rheumatoid Arthritis: The ACT-RAY Study
2012
CTLA-4 directly inhibits osteoclast formation
2008
Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor ? transgenic mice
2001
Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases
2007
Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway
2011
IgG autoantibodies bound to surfaces of necrotic cells and complement C4 comprise the phagocytosis promoting activity for necrotic cells of systemic lupus erythaematosus sera
2007
Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis.
2012
Autoimmunity and rheumatoid arthritis.
2004
W01.41 Osteoprotegerin is a risk predictor of progressive atherosclerosis and cardiovascular disease
2004
SAT0255 Clinical and Radiographic Outcomes at 2 Years and the Effect of TOCILIZUMAB Discontinuation following Sustained Remission in the Second and Third Year of the ACT-RAY Study
2014
Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells
2015
Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade
2010